Renishaw plc (RSW.LSE) Zen Horizon Research Report

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow large is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  Conclusion: Renishaw's market ceiling is large enough, but not unlimited. It is mainly expanding the existing high-end manufacturing precision-metrology pie, while pushing that pie outward into semiconductors, defence, automation, and software-enabled use cases. It is not creating a wholly new category.

  The hardest anchor is the company's own framing: the FY2025 Annual Report puts Renishaw's total serviceable markets at about £6bn and says these markets can grow through the cycle by at least about 5%. Compared with FY2025 revenue of £713.0m, including £671.5m from Manufacturing Technologies and £41.6m from Analytical instruments and medical devices, Renishaw has not saturated its whole serviceable market, but it is no longer an early-stage small company either. Using the report's common price anchor of 5,145p/£51.45 and a market value of about £3.7-4.0bn, its growth case needs to be delivered through many years of compounding, not through a sudden TAM expansion that drives a re-rating.

  In market-nature terms, this is "high-end manufacturing upgrading," not "new-market invention." Renishaw sells CMM probes, machine-tool probes, encoders, calibration, additive manufacturing, spectroscopy, and medical/neurosurgery-related equipment. At root, all of these make manufacturing, inspection, and process control more precise. The annual report attributes growth trends to greater manufacturing-equipment precision, industrial automation, electrification/digitalisation, semiconductors, and low-carbon manufacturing. These are upgrades and premiumisation of existing industrial budgets, not spending categories customers never had before.

  The recent acceleration supports the same view. H1 FY2026 revenue was £365.6m, up 7.1% on an actual basis and 11.5% at constant exchange rates; Q2 was a record quarter, the order book continued to strengthen, and the company specifically called out strong growth in defence and semiconductors. This shows that semiconductor equipment, advanced packaging, EUV-related precision requirements, and defence/aerospace components are indeed expanding demand. But these look more like penetration of precision metrology into higher-value settings than Renishaw creating a completely new consumer or software market.

  So the core judgment for Baillie Question 1 is: the ceiling is "medium-high," but not "extremely high." The positive side is that a £6bn TAM still leaves room against £713m of revenue, while semiconductors, defence, and industrial automation can raise both the per-machine value and penetration of precision metrology. The constraint is that Renishaw is already a de facto standard player in core CMM/metrology areas. Future growth will depend more on share consolidation, product-line extension, service/software attachment, and cyclical recovery than on opening a 10x new market from 0 to 1.

  Jun 8, 2026
• QCan its revenue at least double over the next five years? Will growth be driven mainly by volume, price, or new businesses?3/10

  A

  Conclusion: In the base case, a revenue doubling over the next five years is unrealistic; it only qualifies as a very optimistic upside scenario. Starting from FY2025 revenue of £713M, doubling to about £1.43B requires roughly a 15% CAGR. That is clearly above Renishaw's own disclosed long-term revenue growth target of "high single digits" and its FY2025 five-year average revenue growth rate of 6.9% (see the FY2025 Annual Report). Even though H1 FY2026 has accelerated, full-year revenue guidance is only £740M-£780M (see H1 FY2026 results), up only about 4%-9% from FY2025, which is not the opening pace of a 15% compound growth path.

  Growth will mainly come from "volume + mix," not price. The highlights in H1 FY2026 were demand from semiconductors, defence, electronics manufacturing equipment, and high-end measurement systems: industrial metrology, position measurement, and Specialised Technologies all grew, and the order book also strengthened. The price contribution was very limited. The company explicitly said only 1.4% of H1 growth came from price increases, mainly to offset US tariffs (see H1 FY2026 results), so a doubling cannot be underwritten by sustained ASP increases.

  New businesses are accelerators, but not engines large enough yet. Industrial automation/software, additive manufacturing, enclosed optical encoders, medical/spectroscopy and other new threads can certainly improve growth quality. But FY2025 revenue still relied heavily on Manufacturing Technologies, while Analytical instruments and medical devices contributed only about £41.6M, roughly 6% of the group. To double in five years, small businesses growing from low bases would not be enough; core industrial metrology and position measurement would also need to grow at double-digit rates for several consecutive years.

  My judgment, therefore, is that a five-year doubling requires all three conditions to hold at the same time: continuation of a semiconductor/defence supercycle, successive new products scaling, and M&A or software enablement materially magnifying the business. A more executable path is high-single-digit to low-double-digit revenue growth: semiconductors and defence contribute volume, product upgrades improve mix, and price merely passes through costs/tariffs. At the current price of about 5,145p/£51.45 and market value of about £3.7-4.0B, the market is already paying a high price for this acceleration curve; but "FY2025 £713M to £1.43B in five years" is still not the base expectation.

  Jun 8, 2026
• QAfter five years, what will take over as the next growth engine? Does this "second curve" exist today?4/10

  A

  Conclusion: Around 2031, the most likely successor is not a single new business, but a combination of continued expansion in high-end semiconductor/defence metrology demand and an industrial-automation data platform that turns the installed hardware base into data/software revenue. Strictly speaking, the second curve has product prototypes today, but not financial validation. At the current price of about 5,145p/£51.45 and market value of about £3.7-4.0B, it should not be treated as a growth engine that has already been delivered.

  The layers make the picture clearer:

  Direction	Does it exist today?	Can it count as a second curve?
  Semiconductors/defence	It already exists and is accelerating. H1 FY2026 revenue was £365.6M, up +11.5% at constant exchange rates; the company explicitly said Q2 was a record, the order book strengthened, and semiconductor and defence growth was strong.	This is more like "high-end acceleration of the core business," not an entirely new second curve. The products sold are still encoders, calibration, and metrology systems, and they are affected by fab capex and defence-order lumpiness.
  Industrial automation data platform	The product already exists. Renishaw Central is a platform that connects machine tools and measurement equipment, aggregates process and metrology data, and supports correction and closed-loop control.	This is the closest candidate for a real second curve, because it could extend one-off hardware sales into software, data, and service revenue. But under the report's framing, current revenue is still very small, with no public evidence on ARR, renewal rates, or software gross margin.
  AM additive manufacturing	It already exists. RenAM 500 is an AM system based on metal laser powder bed fusion, and H1 FY2026 also listed it among "emerging product lines" that continue to gain traction.	It has not yet been validated as a group-level curve. It is an extension of engineering capability, but AM equipment adoption is slow and orders are volatile, so it cannot be valued directly as a platform-growth business.
  Medical spectroscopy/neuro-robotics	It exists, but is small. The FY2025 Annual Report shows Analytical instruments and medical devices revenue of about £41.6M, roughly 6% of the group's £713.0M, and the segment consists of spectroscopy and neurological product lines; neuromate is indeed used in stereotactic neurosurgery settings such as DBS, SEEG, biopsy, and neuroendoscopy.	This is more like a long-term option than a main five-year engine. Spectroscopy and robotics are real products, but their revenue scale, growth rate, and profit contribution are not enough to take over from the manufacturing-technology core.

  So the answer is: the second curve "exists in the product roadmap," but not yet in the income statement. Renishaw's handoff logic over the next five years first depends on semiconductors/defence lifting the precision-metrology core to a higher growth tier, and then on whether Renishaw Central can connect the large installed base of probes, encoders, CMMs, and AM systems into a data platform. If, during 2027-2031, the company starts disclosing software/platform revenue, subscription renewals, connected installed-base counts, or data-platform attach rates, and if this visibly raises the service-revenue mix, the second curve would be validated. Until then, AM and medical robotics are real but unscaled options.

  Jun 8, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Conclusion: Renishaw's core moat is "de facto standard in high-precision metrology + switching costs after embedding into customers' production/quality-control workflows," with an outer layer of patient capital from long-term R&D, direct sales/local service, and family control. Over the next three to five years, I tend to think this moat will widen slightly in core CMM/machine-tool probes, encoders, and high-precision semiconductor/defence settings, but it will not become a platform or network-effect moat.

  The first layer is de facto standard status. Renishaw was founded in 1973, and its first product was the touch-trigger probe invented by Sir David McMurtry to solve a measurement problem for the Concorde Olympus engine; the company says this product helped transform 3D coordinate measurement, and that its CMM sensors are the industry standard on many types of CMMs. Once such products enter customers' CMMs, machine tools, encoders, and quality-control workflows, switching is not as simple as comparing supplier quotes. Customers must recalibrate, validate measurement programs, train operators, and bear downtime and yield risk. In other words, its switching costs come from manufacturing quality systems, not contractual lock-in.

  The second layer is engineering investment and service density. Renishaw has long invested about 13%-18% of annual sales in R&D and engineering. The FY2025 Annual Report shows revenue of £713.0m, R&D expenditure of £68.9m, 66 key locations, and 5,342 employees, while emphasising strong IP, R&D investment, local customer support, and technical capability. For customers, probes/encoders are not isolated pieces of hardware; they also involve spares, calibration, repairs, upgrades, software, and field application engineers. Renishaw also explicitly provides engineering support, repair, calibration, training, software, and spare-parts services. This turns a one-off hardware sale into a lifecycle relationship.

  The third layer is ownership structure. Deltam Holdings owns 50.25% of Renishaw's issued share capital and is described as a vehicle for family intergenerational succession and a long-term shareholding commitment. This matters practically for a precision-engineering company: R&D cycles are long, short-term margins are often compressed by R&D and service networks, and family long-termism can tolerate that investment. In H1 FY2026 the company again delivered revenue of £365.6m, constant-currency growth of 11.5%, a stronger order book, and strong semiconductor and defence growth, showing that its core technology still has demand pull in higher-precision manufacturing settings.

  The limitations are also clear: this is not a winner-takes-all network effect. Renishaw protects "engineering trust, process embedding, service responsiveness, and precision reputation," not a product that automatically becomes stronger as more users adopt it. Hexagon has a larger measurement and industrial-software platform, with 29.4% adjusted EBIT1 margin and EUR 567.4m recurring revenue in Q4 2025. Keyence is the efficiency benchmark in automation sensing/inspection, with FY2025 net sales of ¥1,059.1bn and operating income of ¥549.8bn, and publicly shows 51.9% operating profit on sales. So Renishaw's moat is deep in niche settings involving extremely high precision and embedded workflows, but in software enablement, general automation, sales efficiency, and margins it is not as wide as Keyence/Hexagon.

  My judgment, therefore, is: over a three-to-five-year horizon, the moat "widens in the core zone, but not necessarily at the periphery." The core zone will benefit from higher-precision manufacturing, rising customer validation costs, R&D continuity, and Deltam's long-term control. But it remains exposed to cycles in machine tools, semiconductor capital expenditure, and defence orders. Anchored to a price of about 5,145p/£51.45 and market value of about £3.7-4.0B, this moat can protect share and customer stickiness, but it cannot remove cyclicality or guarantee further valuation expansion.

  Jun 8, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  Conclusion: Yes, but this is "reinvention through adjacent engineering expansion," not a complete change of arena. Renishaw's DNA is not limited to selling CMM probes. It goes deep in high-precision measurement, motion control, materials analysis, and factory process control, then extends along customers' manufacturing closed loop. It started with CMM touch-trigger probes, then expanded into position encoders, laser calibration, AM metal 3D printing, Raman spectroscopy, neurosurgical equipment, and the industrial-automation data layer. The FY2025 Annual Report also splits manufacturing technologies into industrial metrology, position measurement, and AM, and splits analytical and medical into spectroscopy and neurological products. So if traditional probes were disrupted, it would not be without alternatives, but the likely migration path would be toward "higher-precision motion control + production-line data + process feedback," not into a completely unfamiliar market.

  Its way of handling bad news is "engineer-like correction": it does not dramatise admissions of error, but it reorganises resources, narrows priorities, and keeps iterating. AM is the clearest example. After metal 3D printing failed to deliver on early expectations for many years, the company did not package it as an already-successful second curve. Instead, it placed AM back inside the manufacturing-technology portfolio and, as early as 2019, concentrated/restructured its AM engineering, commercial, and marketing teams. Later, its framing shifted toward multi-laser systems for high-potential production customers. This shows it can acknowledge that "the direction is right, but commercialisation is slow." The drawback is that adjustment is slow, so AM cannot be treated as a validated growth engine yet.

  The sale process was another stress test for bad news. The founders once initiated a formal sale process, but in 2021 the company terminated the process because no proposal met the Board's objectives for all stakeholders. This was not simply a negative "failed sale." It showed a willingness to review strategic options, and also a willingness to reject unsuitable buyers for the sake of culture, long-term R&D, and independence. Later, Deltam Holdings held 50.25% of the share capital, further shifting the governance anchor from "individual founder" to "family-control structure." That helps sustain long-term R&D, but also means outside shareholders have weaker leverage over the speed of strategic correction.

  The margin target shows whether it is transparent about bad news. FY2025 adjusted operating margin was only 15.7%, while the company's long-term target is above 20%; H1 FY2026 revenue rose to £365.6M with constant-currency growth of 11.5%, but adjusted operating margin was still 15.7%. This shows operating improvement is progressing, but the margin inflection has not truly arrived. Management frames the issue around productivity, fixed-cost control, and Operating Excellence, which is relatively clear; but investors need to see actual delivery at 17%-18% and then 20%, not only hear the target.

  So the judgment on Question 5 is: Renishaw has reinvention capability, and that capability comes from a deep engineering stack, long-term R&D investment, and problem-solving at customer sites. But it is not a high-speed, high-churn reinvention machine. The current price of about 5,145p/£51.45 and market value of about £3.7-4.0B already embed a premium for "good company + long-termism + semiconductor/defence/automation adjacency." To truly prove reinvention, AM needs to stop dragging, the industrial-automation data platform needs to turn from small revenue into a visible annuity, and the 15.7% margin needs to make substantive progress toward the 20% target.

  Jun 8, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profits for outcomes five to ten years out?6/10

  A

  Conclusion: Renishaw has "strong owner anchor + engineer-manager" governance, but it is not the highest form where the founder is still personally at the helm. Sir David McMurtry died on 2024-12-09; the core of long-termism now mainly comes from McMurtry/Deer family control through Deltam. Company announcements show that Deltam Holdings owns 50.25% of Renishaw's issued share capital, and that its purposes include intergenerational succession and a reaffirmed long-term shareholder commitment. This makes the company more resistant to quarterly profit pressure than a typical professionally managed industrial company.

  CEO Will Lee is also not an external finance-type CEO, but an internally developed engineering-oriented manager: Renishaw's leadership page discloses that Will Lee joined the company's graduate scheme in 1996, then held roles across engineering, operations, sales, and marketing, and has been CEO since 2018. Founder continuity remains at Board level: John Deer remains a Non-executive Director and participates in Board leadership and strategic decision-making, and the FY2025 Annual Report also notes that the Board appointments of Richard McMurtry and Camille Deer reflect the founding family's continuing commitment to the company's future.

  Is it willing to sacrifice current profits for outcomes five to ten years out? The answer is yes, but with boundaries. The most direct evidence is the company's continued allocation of resources to future technologies: the FY2025 Annual Report discloses R&D expenditure of £68.9m and gross engineering expenditure of £120.1m. For a hardware company with FY2025 revenue of £713m and adjusted operating margin of 15.7%, this kind of engineering investment materially depresses current margins, but supports long-term technology assets in probes, encoders, metrology software, and medical/spectroscopy products.

  The deduction is that Will Lee's personal economic alignment is not "founder-level." The FY2025 Annual Report discloses that the minimum shareholding guideline for executive directors is 2x salary, while Will Lee's actual holding at the time was 0.813x salary; the incentive mechanism also has a high share linked to adjusted PBT. This indicates the company will balance long-term R&D, margin repair, and cost control, rather than sacrificing short-term profit unconditionally.

  So the judgment on Question 6 is: Renishaw's owner alignment is clearly stronger than that of an ordinary listed industrial company, and Deltam's 50.25% family control is the key positive. But the founder has passed away, and the CEO's personal shareholding is not on the same scale as founding-family control. Anchored to a price of about 5,145p/£51.45 and total market value of about £3.7-4.0B, this long-termism is already an important reason why the market is willing to pay Renishaw a premium, but it is more like stable long-term owner governance than an extreme owner-operator model still personally driven by the founder.

  Jun 8, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth model sustainable and not dependent on harming society or regulation?6/10

  A

  Conclusion: Customers would clearly miss Renishaw, but it is not an irreplaceable natural monopoly; its growth path is generally positive in externalities and relatively sustainable from a regulatory perspective, although defence, export controls, and manufacturing cycles need clear boundaries. Anchored to a price of about 5,145p/£51.45 and market value of about £3.7-4.0B, it looks more like "high-end manufacturing quality-control infrastructure" than a company growing through regulatory arbitrage or outsourced social costs.

  Customer stickiness comes from workflow embedding. Once probes, encoders, and calibration systems enter machine tools, CMMs, semiconductor equipment, or aerospace/medical quality systems, replacement is not a matter of changing a purchase order. It means recalibration, software-interface changes, process revalidation, and training. Renishaw's FY2025 Manufacturing Technologies revenue was £671.5m, out of group revenue of £713.0m, showing that the core business is almost entirely organised around manufacturing measurement and control. In H1 FY2026 the company also said its products give customers high precision, traceability, and confidence in manufacturing. So if it disappeared tomorrow, customers' short-term pain would be downtime risk, yield volatility, and quality-control recertification, not simply paying more money.

  But substitutes still exist. Hexagon, ZEISS, Mitutoyo, Keyence, Heidenhain, and others all have strong products across measurement, sensing, automation, and encoders, and large customers also retain second sources. Renishaw's advantages are high switching costs, engineering trust, long-tail service, and de facto-standard habits, not a world where customers have no alternatives forever. If delivery, pricing, or product iteration falls behind, customers will migrate; the migration cost is just high and the cycle long.

  Social and regulatory sustainability is generally positive: precision metrology catches defects during production, reducing rework, scrap, recalls, and safety incidents, and it creates positive quality-control externalities for aerospace, medical, semiconductor, automotive, and high-end equipment manufacturing. In H1 FY2026, the company also attributed structural demand to higher manufacturing precision, automation, digitalisation, decarbonisation, and semiconductor, defence, and electrification demand. This growth is not based on tobacco- or gambling-like negative externalities; it helps complex manufacturing become more reliable.

  The boundaries are in three places. First, defence/aerospace demand will pull precision metrology, but orders are lumpy and more affected by policy and budget cycles. Second, precision sensing, lasers, encoders, and semiconductor-manufacturing-related equipment have dual-use characteristics; the UK has an export-licensing framework for dual-use items, software, and technology, and Renishaw's annual report also acknowledges rising complexity in export controls and global trade compliance. Third, it remains in the manufacturing hardware chain, where machine-tool, semiconductor capex, and defence orders can all fluctuate cyclically. Overall, customers would miss it, and growth is broadly sustainable; but defence and regulated semiconductor demand should not be treated as a risk-free perpetual curve.

  Jun 8, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or deteriorate with scale? Where does the money it earns go?5/10

  A

  Conclusion: Renishaw's unit economics are a high-quality industrial-hardware model of "high-gross-margin hardware + long-tail service + high engineering investment." They are likely to improve with scale, but this is not a top-tier margin model like Keyence. Its product gross-margin foundation is decent: FY2025 gross margin, excluding engineering costs, was 61.7%. After probes, encoders, and calibration instruments are sold, they also bring aftermarket service revenue from repairs, maintenance, training, extended warranties, software licences, and maintenance. The issue is that, at group level, Renishaw must keep funding R&D, engineering, manufacturing, direct sales, and a global service network, so the result is only FY2025 adjusted operating margin of 15.7%, with a target above 20%, and H1 FY2026 was still 15.7%.

  Incremental returns are above average, but this is not a model where every unit of capital invested scales exponentially. FY2025 ROIC was 12.6%, and H1 FY2026 mentioned 13.2%, showing it can make money and has decent cash quality, but it remains short of the company's 15% ROIC target and 20%+ margin target. The real benefit of scale is in spreading fixed engineering, manufacturing, and sales/service costs, and bringing more installed equipment into spare-parts, calibration, and software-maintenance cycles. But after H1 FY2026 revenue grew 11.5% at constant exchange rates, the margin still stayed at 15.7%, showing that FX, tariffs, product mix, and engineering investment can absorb part of the operating leverage.

  Compared with peers, Renishaw is a good business, but not the ceiling of the category. Keyence FY2025 net sales were ¥1.059 trillion and operating income was ¥549.8 billion, implying an operating margin of about 52%; Hexagon's 2025 EBIT1 margin was 26.8% and EBITAC margin was 23.2%. Renishaw's 15.7% is clearly a tier lower, so it should not be priced with "British Keyence" margin imagination.

  The money it earns mainly goes to three places. First, the moat: FY2025 total engineering costs were £106.8m, about 15% of revenue, including £68.9m of R&D expenditure. Second, capacity and efficiency: FY2025 capital expenditure was £46.3m, and H1 FY2026 continued to invest in equipment, automation, and IT transformation. Third, conservative capital allocation: FY2025 dividends paid were £55.4m, while the company retained a thick net-cash position, with FY2025 cash and bank deposits of £273.6m and borrowings of only about £2.8m; H1 FY2026 still had £240.9m of cash and deposits. At a share price of about 5,145p/£51.45 and market value of about £3.7-4.0B, the market is already asking these unit economics to continue improving toward a 20% margin, not merely maintain the current 15.7%.

  Jun 8, 2026
• QWhat conditions would have to hold for it to rise 5x over 10 years? Are those conditions realistic? What expectations are implied by today's share price?2/10

  A

  Conclusion: At the current price of about 5,145p/£51.45 and market value of about £3.7-4.0B, a 5x return over 10 years would mean roughly £257/share and equity value close to £19B. That requires more than a "good company keeps getting better" story. Renishaw would need to move from being a hidden champion in precision metrology to a high-growth, high-margin global automation/semiconductor metrology platform that still enjoys a high valuation. The realism is low.

  The conditions that need to hold simultaneously are roughly threefold. First, revenue must move from the FY2026 guidance midpoint of about £760M into many years of high compounding, reaching at least the £3B+ range after 10 years, rather than the mature-industrial growth profile of FY2025 revenue of £713M and growth of 3.1%; semiconductors, defence, industrial automation, software data platforms, and medical/spectroscopy all need to hand off successfully. Second, margins need to move clearly above 20%+ from the current roughly 15.7% adjusted operating margin, without R&D intensity overwhelming operating leverage; the company's H1 FY2026 revenue of £365.6M, constant-currency growth of 11.5%, and adjusted operating margin still at 15.7% show that a growth inflection has appeared, but the margin step-up has not been delivered. Third, EPS/FCF per share must grow severalfold while the terminal valuation multiple does not compress materially. Using FY2026E EPS of about £1.59 as a rough base, if the market still applies a 30x PE after 10 years, a £257 share price requires EPS of about £8.6, or roughly 5.4 times current per-share earnings; if the market assigns only a 25x PE, EPS needs to reach about £10.3, close to 6.5 times.

  These conditions are not impossible individually, but achieving them simultaneously is hard. Renishaw has advantages including de facto standard status, switching costs, net cash, and family control. But it remains primarily an industrial-hardware company, not a pure software platform; orders are affected by semiconductor, machine-tool, and defence cycles; the software/data platform is still small; and additive manufacturing has not yet proved it can become a large curve. A more realistic upside scenario is margin repair to 18%-20%, revenue growth sustained in the medium-high single digits to low double digits, and the share price reaching the report's optimistic range. For a 5x return over 10 years, semiconductor metrology and automation would need to outperform expectations for a long period, and the market would need to keep valuing it as a high-quality growth stock.

  Today's share price of about £51.45 implies that the market already believes in FY2026 acceleration, continued semiconductor/defence demand, partial delivery of the 20% margin path, and a premium for family long-termism. It looks more like the "good script" has already been priced in, rather than a cheap starting point for a 5x return over 10 years. Unless subsequent revenue compounding and margin improvement keep beating expectations, the current price is closer to fairly expensive than to an asymmetric 5x Baillie-style opportunity.

  Jun 8, 2026
• QWhy has the market not realised all this yet? Is it because the market does not understand, does not respect it, or cannot look far enough ahead? What would become the "narrative inflection point"?3/10

  A

  Conclusion: The market has not completely missed it; it has already seen half of the story and paid a meaningful price for it. In H1 FY2026, Renishaw disclosed revenue of £365.6m, constant-currency growth of 11.5%, adjusted operating margin of 15.7%, a continuing strengthening of the order book, and clearly strong semiconductor and defence demand. Since then, the share price has already rebounded sharply to about 5,145p/£51.45, with market value of about £3.7-4.0B. The key question now is not "the market has not noticed," but whether the market is willing to reprice it from a high-quality cyclical industrial stock into a semiconductor/defence precision-manufacturing platform stock.

  Why has it only seen half? All three factors are present.

  First, there is some failure to understand. On the surface, Renishaw is a UK industrial-hardware company whose revenue growth over the past few years has not been striking. But its real value lies in the depth of embedding in customers' production and quality-control workflows, the long tail of calibration/spares, and the key role of encoders and high-precision metrology in semiconductor equipment. In the FY2025 Annual Report, the company disclosed revenue of £713.0m and adjusted profit before tax of £127.2m, and stressed its aim to lift adjusted operating margin from 15.7% to above 20%. This is not a simple revenue recovery; it is an operating-leverage re-rating.

  Second, there is some underestimation. The market still places it in the box of "machine-tool cycle + UK mid-cap industrial + family-control liquidity discount." That framework is not entirely wrong: its moat can protect share and customer stickiness, but cannot eliminate cyclicality in semiconductor, machine-tool, and defence orders; the current 30x+ forward PE is also not cheap.

  Third, there is some short horizon. Deltam's 50.25% family control, fixed through the shareholdings update, gives the company conditions to keep investing in R&D, product platforms, and long-term customer relationships. But the market usually waits for margins and orders to be delivered across consecutive periods before pricing this kind of long-termism.

  There are three real upside narrative inflection points. First, adjusted operating margin needs not merely to remain at 15.7%, but to move steadily into 17%-18% and then make the 20% target credible. Second, semiconductor and defence orders need to stay strong for several reporting periods, proving this is not a one-off H1 FY2026 restocking effect. Third, industrial automation, metrology systems, and software platforms need to disclose clearer revenue mix, retention, or subscription characteristics, so the market can see the valuation potential of "hardware leader + data/software layer."

  The downside inflection points are just as clear: if margins get stuck at only 17%-18%, semiconductor orders roll over with the fab cycle, defence orders show lumpiness, or the software platform remains a small-volume narrative for too long, the current high valuation will turn from an advantage into pressure. In other words, Renishaw's misunderstanding is not that "the market is completely wrong." The market already accepts it as a good company, but does not yet have enough evidence to accept it as a platform-like growth asset capable of sustained re-rating.

  Jun 8, 2026